Genmab A/S (GNMSF) Interest & Investment Income (2019 - 2026)

Genmab A (GNMSF) has 7 years of Interest & Investment Income data on file, last reported at $44.0 million in Q1 2026.

• Quarterly Interest & Investment Income fell 56.44% year-over-year to $44.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $710.0 million (down 19.41% YoY) and the FY2025 annual result came in at $408.0 million, down 36.74% from the prior year.
• Interest & Investment Income fell to $44.0 million in Q1 2026, from $312.0 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $328.0 million in Q3 2024 to a low of $44.0 million in Q1 2026.
• A 4-year average of $203.4 million and a median of $210.5 million in 2024 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2025 — Interest & Investment Income dropped 4.88% — and 2026, when it slumped 56.44%.
• Tracing GNMSF's Interest & Investment Income over 4 years: stood at $137.0 million in 2023, then surged by 139.42% to $328.0 million in 2024, then declined by 4.88% to $312.0 million in 2025, then plunged by 85.9% to $44.0 million in 2026.
• The last three Interest & Investment Income figures came in at $44.0 million (Q1 2026), $312.0 million (Q3 2025), and $253.0 million (Q2 2025), per Business Quant data.